38
Participants
Start Date
June 28, 2016
Primary Completion Date
March 31, 2017
Study Completion Date
March 31, 2017
interferon γ-1b
ACTIMMUNE® will be administered three times per week by subcutaneous injection. The initial dose will be individualized for each participant and will be determined by the investigator, provided that the initial dose does not exceed the maximum tolerated dose in HZNP-ACT-302 (NCT02593773). The investigator may subsequently adjust the dose for any participant if deemed clinically appropriate, provided that the dose does not exceed 100 μg/m².
Children's Hospital of Philadelphia, Philadelphia
University of Florida Clinical Research Center, Gainesville
University of Iowa Children's Hospital, Iowa City
University of California, Los Angeles Neurology Clinic, Los Angeles
Lead Sponsor
Friedreich's Ataxia Research Alliance
OTHER
Amgen
INDUSTRY